A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications.
Compounds which increase the capacity to conceive in females.
A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.
Extracts of urine from menopausal women that contain high concentrations of pituitary gonadotropins, FOLLICLE STIMULATING HORMONE and LUTEINIZING HORMONE. Menotropins are used to treat infertility. The FSH:LH ratio and degree of purity vary in different preparations.
Techniques for the artifical induction of ovulation, the rupture of the follicle and release of the ovum.
Receptors with a 6-kDa protein on the surfaces of cells that secrete LUTEINIZING HORMONE or FOLLICLE STIMULATING HORMONE, usually in the adenohypophysis. LUTEINIZING HORMONE-RELEASING HORMONE binds to these receptors, is endocytosed with the receptor and, in the cell, triggers the release of LUTEINIZING HORMONE or FOLLICLE STIMULATING HORMONE by the cell. These receptors are also found in rat gonads. INHIBINS prevent the binding of GnRH to its receptors.
A synthetic prostaglandin F2alpha analog. The compound has luteolytic effects and is used for the synchronization of estrus in cattle.
An assisted reproductive technique that includes the direct handling and manipulation of oocytes and sperm to achieve fertilization in vitro.
A potent synthetic agonist of GONADOTROPIN-RELEASING HORMONE with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central PRECOCIOUS PUBERTY and ENDOMETRIOSIS.
A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity.
A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.
The transfer of mammalian embryos from an in vivo or in vitro environment to a suitable host to improve pregnancy or gestational outcome in human or animal. In human fertility treatment programs, preimplantation embryos ranging from the 4-cell stage to the blastocyst stage are transferred to the uterine cavity between 3-5 days after FERTILIZATION IN VITRO.
A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue. Note that ENCLOMIPHENE and ZUCLOMIPHENE are the (E) and (Z) isomers of Clomiphene respectively.
The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS.
An OOCYTE-containing structure in the cortex of the OVARY. The oocyte is enclosed by a layer of GRANULOSA CELLS providing a nourishing microenvironment (FOLLICULAR FLUID). The number and size of follicles vary depending on the age and reproductive state of the female. The growing follicles are divided into five stages: primary, secondary, tertiary, Graafian, and atretic. Follicular growth and steroidogenesis depend on the presence of GONADOTROPINS.
A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity (CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN).
Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.
The ratio of the number of conceptions (CONCEPTION) including LIVE BIRTH; STILLBIRTH; and fetal losses, to the mean number of females of reproductive age in a population during a set time period.
Occurrence or induction of ESTRUS in all of the females in a group at the same time, applies only to non-primate mammals with ESTROUS CYCLE.
The period in the MENSTRUAL CYCLE that follows OVULATION, characterized by the development of CORPUS LUTEUM, increase in PROGESTERONE production by the OVARY and secretion by the glandular epithelium of the ENDOMETRIUM. The luteal phase begins with ovulation and ends with the onset of MENSTRUATION.
In females, the period that is shortly after giving birth (PARTURITION).
The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE.
The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.
The yellow body derived from the ruptured OVARIAN FOLLICLE after OVULATION. The process of corpus luteum formation, LUTEINIZATION, is regulated by LUTEINIZING HORMONE.
The discharge of an OVUM from a rupturing follicle in the OVARY.
Pharmacologic agents delivered into the nostrils in the form of a mist or spray.
Delivery of medications through the nasal mucosa.
A protein extract of human menopausal urine in which LUTEINIZING HORMONE has been partially or completely removed. Urofollitropin represents FOLLICLE STIMULATING HORMONE from the urine.
The mucous lining of the NASAL CAVITY, including lining of the nostril (vestibule) and the OLFACTORY MUCOSA. Nasal mucosa consists of ciliated cells, GOBLET CELLS, brush cells, small granule cells, basal cells (STEM CELLS) and glands containing both mucous and serous cells.
A small, unpaired gland situated in the SELLA TURCICA. It is connected to the HYPOTHALAMUS by a short stalk which is called the INFUNDIBULUM.
The anterior glandular lobe of the pituitary gland, also known as the adenohypophysis. It secretes the ADENOHYPOPHYSEAL HORMONES that regulate vital functions such as GROWTH; METABOLISM; and REPRODUCTION.
Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).
Clinical and laboratory techniques used to enhance fertility in humans and animals.
Inability to reproduce after a specified period of unprotected intercourse. Reproductive sterility is permanent infertility.
The capacity to conceive or to induce conception. It may refer to either the male or female.
A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.
Tumors or cancer of the PROSTATE.
Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM.
A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.
Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.
Derivatives of ACETIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxymethane structure.
Pain in the pelvic region of genital and non-genital origin and of organic or psychogenic etiology. Frequent causes of pain are distension or contraction of hollow viscera, rapid stretching of the capsule of a solid organ, chemical irritation, tissue ischemia, and neuritis secondary to inflammatory, neoplastic, or fibrotic processes in adjacent organs. (Kase, Weingold & Gershenson: Principles and Practice of Clinical Gynecology, 2d ed, pp479-508)
The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo.
Pathological processes involving the PERITONEUM.

A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study. (1/216)

The use of gonadotrophin-releasing hormone analogues (GnRHa) has resulted in improved pregnancy rates in in-vitro fertilization (IVF) treatment cycles. Traditionally, short-acting analogues have been employed because of concerns over long-acting depot preparations causing profound suppression and luteal phase defects adversely affecting pregnancy and miscarriage rates. We randomized 60 IVF patients to receive a short-acting GnRHa, nafarelin or buserelin, or to receive a depot formulation, leuprorelin, all commenced in the early follicular phase and compared their effects on hormonal suppression and clinical outcome. We found that on day 15 of administration there was a significant difference in the suppression of oestradiol from initial concentrations, when patients on buserelin were compared with patients on nafarelin or leuprorelin (54 versus 72 and 65%; P < 0.05) and also in the number of patients satisfactorily suppressed, (80 versus 90 and 90%; P < 0.05), though there were no differences between the analogues by day 21. Similarly there was no difference in hormonal suppression during the stimulation phase or in implantation, pregnancy or miscarriage rates in comparing the three agonists. We conclude that with nafarelin and leuprorelin, stimulation with gonadotrophins may begin after 2 weeks of suppression and that long-acting GnRHa are as effective as short-acting analogues with no detrimental effects on the luteal phase.  (+info)

The pattern of changes in ovarian stromal and uterine artery blood flow velocities during in vitro fertilization treatment and its relationship with outcome of the cycle. (2/216)

OBJECTIVES: To assess the effect of short-term (2-3 weeks) pituitary suppression and controlled ovarian stimulation on ovarian and uterine artery Doppler measurements during the in vitro fertilization (IVF) treatment cycle and to compare the pattern of these changes between conception and non-conception cycles as well as between patients with normal and those with polycystic ovaries. DESIGN: Prospective observational study of women undergoing IVF treatment. SUBJECTS: Women using the long-treatment buserelin protocol who did not have uterine fibroids, ovarian cysts or endometrioma. METHODS: Serial transvaginal color and pulsed Doppler measurements of ovarian stromal and uterine artery blood flow velocity were carried out in the early follicular phase of the menstrual cycle, on the day of pituitary suppression and on the day of administration of human chorionic gonadotropin (hCG). The main outcome measures were the ovarian stromal and uterine artery blood flow peak systolic velocity (PSV) and pulsatility index (PI). RESULTS: A total of 105 patients were recruited but six patients were excluded from the analysis because they had only one stage of the measurements performed. There was a significant decline in mean ovarian stromal artery PSV after 2-3 weeks of gonadotropin releasing hormone (GnRH) agonist therapy but no effect on ovarian stromal artery PI. The mean uterine artery PSV or PI did not change significantly after 2-3 weeks of GnRH agonist therapy. There was a significantly higher mean ovarian stromal artery PSV in conception cycles compared to non-conception cycles in the early follicular phase and on the day of pituitary suppression, but not on the day of hCG administration. There were no differences between conception and non-conception cycles in the mean uterine artery PSV or PI. Women with polycystic ovaries had a higher mean ovarian artery PSV on all the three occasions of measurement. CONCLUSION: These data suggest that assessment of ovarian blood flow before commencement of gonadotropin stimulation may play a role in assessing cycles likely to result in pregnancy.  (+info)

Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist? (3/216)

Gonadotrophin-releasing hormone (GnRH) regulates gonadotrophin release. It has been shown that GnRH may have a direct effect on the ovary, as the addition of GnRH to granulosa cell cultures inhibits the production of progesterone and oestradiol. Specific GnRH receptors have been found to be present in rat and human granulosa cells. Desensitization of the pituitary by GnRH agonist has become common in in-vitro fertilization (IVF) treatment, usually by a long protocol of 2-3 weeks. With the introduction of GnRH antagonists, which produce an immediate blockage of the GnRH receptors, a much shorter exposure is needed of 3-6 days. The aim of this study was to evaluate the effect of a GnRH agonist (buserelin) and a GnRH antagonist (cetrorelix) on the function of granulosa cells cultured in vitro from IVF patients. Women were treated by IVF randomized either to have buserelin nasal spray from the luteal phase in the previous cycle or cetrorelix from day 6 of the cycle. Both groups had ovarian stimulation with human menopausal gonadotrophin (HMG) 150 IU daily, i.e. HCG was administered when the follicles were larger than 17 mm, and aspirated 36 h later. Granulosa cells, separated and washed from large follicles containing ova, were pooled. After 48 h of pre-incubation, the granulosa cells were cultured for 4 days in medium with either added testosterone or cAMP with or without HCG, with change of medium after 2 days. The progesterone and oestradiol concentrations in the culture medium were measured by immunological assay, and cellular protein was measured by microprotein assay. The results showed that granulosa cells from women treated with GnRH antagonist (cetrorelix) responded earlier to the in-vitro hormone stimulation in terms of progesterone accumulation than women treated with the GnRH agonist (buserelin). This may have been due to difference in time of exposure to the analogue. The results may indicate that the luteal function is less impaired in GnRH antagonist treatment than in GnRH agonist treatment.  (+info)

A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. (4/216)

A prospective, randomized, double-blind, multicentre (n = 5) study was conducted to compare the influence of either a 100 or 200 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH) on the number of oocytes retrieved and the total dose used in down-regulated women undergoing ovarian stimulation. Fertilization was done by intracytoplasmic sperm injection or conventional in-vitro fertilization. A total of 199 women were treated with FSH, 101 subjects with 100 IU and 98 subjects with 200 IU. In subjects of the 200 IU treatment group, significantly more oocytes were retrieved compared to the 100 IU group (10.6 versus 6.2 oocytes, P < 0.001). The total dose needed to develop at least three follicles with a diameter of > or = 17 mm was significantly lower in the 100 IU treatment group (1114 IU versus 1931 IU, P < 0.001). In the low-dose group, significantly lower serum concentrations of oestradiol, progesterone and FSH were observed at the day of human chorionic gonadotrophin administration. Although more cycle cancellations due to low response were seen in the 100 IU group (n = 24 versus n = 3), the clinical pregnancy rate per started cycle was similar (24.7% in the 100 IU group versus 23.3% in the 200 IU group). In the high-dose group, more side-effects, in particular more cases of ovarian hyperstimulation syndrome, were noted. It is concluded that compared to 200 IU, the use of a 100 IU fixed dose is less efficacious in terms of the number of oocytes retrieved, but more efficient as indicated by a lower total dose.  (+info)

Prevention of premenstrual exacerbation of hereditary coproporphyria by gonadotropin-releasing hormone analogue. (5/216)

A 20-year-old Japanese female needed frequent hospitalization due to premenstrual exacerbation of hereditary coproporphyria (HCP). Intranasal buserelin acetate, a gonadotropin-releasing hormone analogue, was given to suppress her menstrual cycles. Her porphyric symptoms subsided dramatically as she became amenorrhoeic. Urinary excretion of porphyrin derivatives fell significantly. She has been free from recurrent attacks, but suffers a minor porphyric attack once in 5 years. However, borderline osteopenia secondary to hypoestrogenism has been noted. Although these analogues are potent in suppressing estrogen-induced porphyric symptoms, due precautions should be taken to avoid bone demineralization in the long-term use.  (+info)

Persistent dominant follicle alters pattern of oviductal secretory proteins from cows at estrus. (6/216)

The experimental objective was to compare synthesis of oviductal secretory proteins of dairy cows bearing a persistent dominant follicle (PDF) versus a fresh dominant follicle (FDF) at estrus. On Day 7 after synchronized estrus (Day 0), cows received an intravaginal progesterone device and injection of prostaglandin F2alpha (PGF2alpha). On Day 9, cows received an injection of a GnRH agonist (FDF group; n = 3) or received no injection (PDF group, n = 3). On Day 16, all cows received PGF2alpha, and progesterone devices were removed. At slaughter on Day 18 or Day 19, oviducts ipsilateral and contralateral to the dominant follicle were divided into infundibulum, ampulla, and isthmus regions. Explants from oviductal regions were cultured in minimal essential medium supplemented with [3H]leucine for 24 h. Two-dimensional fluorographs of proteins in conditioned media were analyzed by densitometry. Rate of incorporation of [3H]leucine into macromolecules was greater in the infundibulum, ampulla, and isthmus of FDF cows (p < 0.01). Overall, intensities of radiolabeled secretory protein (P) 2 and P13 were greater for FDF than for PDF. In the ampulla, P14 was more intense for FDF while P7 was more intense for PDF. Abundance of P1 in the isthmus was greater for PDF cows. Across regions, P5, P6, P8, P9, and P11 were more intense for PDF than for FDF in the ipsilateral side. In the contralateral side, P19 was more intense for PDF than for FDF, whereas P6, P8, P9, and P11 were more intense for FDF. Differences in biosynthetic activity and in secreted oviductal proteins from cows bearing a PDF may contribute to the decrease in fertility associated with a PDF.  (+info)

The effect of smoking on oocyte quality and hormonal parameters of patients undergoing in vitro fertilization-embryo transfer. (7/216)

PURPOSE: The aim of the present study was to investigate the influence of smoking on different parameters such as oocyte count, embryo score, and basal hormone values within the scope of in vitro fertilization-embryo transfer (IVF-ET). METHODS: Eight hundred thirty-four women undergoing IVF-ET treatment were classified as smokers or nonsmokers on the basis of questionnaires. Additionally, we divided them into three groups according to their stimulation protocol--"combined stimulation" [I; clomiphene citrate plus human menopausal gonadotropin (hMG)], "ultrashort" [II; gonadotropin releasing hormone agonist (GnRHa) plus hMG or follicle-stimulating hormone (FSH)], and "long downregulation protocol" (III)--and further classified again as smokers or nonsmokers within the groups. RESULTS: In general, smoking patients were significantly (P = 0.0195) younger than nonsmokers and showed a significantly (P = 0.0379) lower embryo score and a tendency (P = 0.0931) to produce fewer oocytes. There was no significant difference concerning the number of normally or pathologically fertilized and transferred oocytes and embryos suitable for cryopreservation. Women who smoked had significantly (P = 0.0112) higher basal 17-beta-estradiol (E2), luteinizing hormone (LH) (P = 0.0001), and dehydroepian-drosteronesulfate (DHEAS) (P = 0.0039) levels, but their basal human prolactin (HPRL) levels were significantly (P = 0.0033) lower than those of nonsmokers. According to the stimulation protocol used, we found the following results. Smoking patients in group I showed a significantly (P = 0.023) lower embryo score and produced fewer oocytes (P = 0.0113), with fewer of them being fertilized (P = 0.0072) and transferred (P = 0.0067). Women who smoked had significantly (P = 0.0002) higher basal LH levels, but their HPRL levels were significantly (P = 0.031) lower than those of nonsmokers. Furthermore, they had a thinner endometrium on the day of embryo transfer (P = 0.0366). In group II we measured significantly elevated basal E2 levels (P = 0.0089) and higher LH values (P = 0.0092) in smokers. Group III showed a trend (P = 0.0565) toward lower HPRL values in smokers. CONCLUSIONS: Although the fertilization rate of oocytes and the pregnancy rate were not significantly different between smokers and nonsmokers, we found significantly alterated hormonal parameters and negatively influenced oocyte parameters, particularly after clomiphene stimulation. So we might consider using only GnRHa protocols for smoking patients. Additionally, we advise our patients to stop smoking before an IVF-ET treatment because of the complex effects of smoking on the reproductive and hormonal system.  (+info)

Involvement of parathyroid hormone-related peptide in cell proliferation activity of human uterine leiomyomas. (8/216)

Uterine leiomyomas develop from uterine smooth muscle cells, which are known to be regulated by estrogen and other growth factors. The purpose of this study was to investigate the role of expression of parathyroid hormone related-peptide (PTHrP) in the growth of uterine leiomyomas treated or untreated with gonadotropin-releasing hormone agonist (GnRH-a). Thirty-nine leiomyoma tissues were obtained from 36 patients who had been treated with GnRH-a (n=10) or without GnRH-a (n=29). The intensity of PTHrP immunostaining was categorized into three grades; "negative", "weakly positive", and "positive". Leiomyoma cell growth was estimated by the proliferating cell nuclear antigen (PCNA) labeling index (LI) with an image analyser. We also investigated the correlation between PTHrP expression and cell proliferation or histopathological findings. In the GnRH-a-untreated group, LI of the PTHrP "positive" group was significantly higher than that of the PTHrP "negative" group, but the intensity of PTHrP immunostaining did not correlate with LI in the GnRH-a-treated group. PTHrP expression did not correlate with histological findings or clinical parameters (age and phase of menstrual cycle) in either the GnRH-a-treated or the -untreated group. In addition, the expression of mRNA for PTHrP and its receptor was detected in leiomyomas by reverse transcriptase-polymerase chain reaction (RT-PCR). Our results indicate that the expression of PTHrP in leiomyomas correlated positively with cell growth in the GnRH-a-untreated group, suggesting that PTHrP may act as a local cell growth modifier in an autocrine/paracrine fashion on uterine leiomyomas.  (+info)

Buserelin is a synthetic form of a hormone which occurs naturally in your body. Buserelin for women is used as part of fertility treatment.
Does any one out there know if you have to reduce the dose of buserelin nasal spray once you have achieved down regulation? Im using suprecur at a dose of 150mg ( one puff) four times a day. Im about to start menopur injections, and my clinic is unsure whether the dose needs to be reduced. They normally use buserelin injections, and they do reduce these to a maintanance dose, but they have no experience with the spray. Any info gratefully recieved. Good luck to every one! Ollies ...
Read about Suprefact, a medication used as a spray or under-the-skin injection to ease the symptoms of pain associated with endometriosis.
Kisspeptin is a neuropeptide that governs the reproductive axis upstream to GnRH. We wanted to study whether kisspeptin modulates plasma LH and FSH levels and ovarian follicular dynamics in buffaloes and whether kisspeptin can be used for fixed time artificial insemination (FTAI). We carried out these studies in comparison with buserelin, a potent GnRH agonist. Kisspeptin dose-dependently increased plasma LH levels. However, the kisspeptin-induced increase in LH was short-lived as the peak reached in 15-30 min returned to basal values by 1-2 h. The kisspeptin-induced increase in LH level was less compared to buserelin-induced increase in LH level which sustained over time. Kisspeptin did not enhance FSH release while buserelin resulted in a gradual increase over time. LH response to repeated injections of kisspeptin was greater than that induced by buserelin. While buserelin induced an increase in the number of follicles, kisspeptin induced an increase in the growth rate of the follicle. In adult
Buserelin belongs to the group of gonadotrophin releasing hormone (gonadorelin) analogues (LHRH agonist). It acts on the pituitary gland which controls the amount of many different types of hormones (chemical messengers). It alters the amount of hormones, particularly the oestrogens androgens. This alteration of hormone levels can be exploited to treat cancers of the prostate gland, which are stimulated to grow by testosterone. Buserelin lowers the levels of testosterone, which starves the tumour of testosterone and causes it to shrink. Buserelin contains 9 amino acids Glu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt and having a molecular weight of 1239.44 Dalton.
DRs (Type G) from 23 January to 4 February. Between 2 and 6 February these hinds received 4 injections of buserelin at a high (4,3,2 and 10 µg respectively) dosage regime. Group H and L hinds (n = 12) received CIDR treatment from 5 February to 17 February. Ovulation was synchronised in Group HH hinds on 17 February with a prostaglandin analogue. All treated hinds received 4 i.m. injections of buserelin between 15 and 19 February at either the high (Groups HH and H) or low (2, 1, 1, and 4 µg respectively; Group L) dosage regimes. Control hinds (n = 12) received no treatment throughout the experiment. All groups were run with a stag (in which rutting had been advanced with melatonin implants) from 18 February, and hinds were observed for 45 hours from this time for oestrus and mating. These events failed to occur and ovulation was again synchronised in all treated hinds on 29 February with prostaglandin analogue. Half (i.e. 6) of the hinds in each of the treated groups received buserelin ...
bew-sĕ-rel-in). a gonadorelin analogue that is administered as a nasal spray or by subcutaneous injection for the treatment of endometriosis and to help in the management of advanced prostate cancer. Trade names:. Suprecur,. Suprefact. ...
Serum concentrations of luteinising hormone and testosterone were measured by radioimmunoassay one, two, four, seven, and 24 hours after the subcutaneous administration of 500 micrograms of the luteinising hormone releasing hormone agonist [D-Trp6, des-Gly-NH2(10)] LHRH ethylamide or [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide in patients who had previously received daily treatment with these peptides for 0, 1, 6, 12, 18, and 24 months. No increase in the serum concentrations of luteinising hormone or testosterone were detected at any time between one and 24 months treatment. The data show that daily subcutaneous administration of the two luteinising hormone releasing hormone agonists used at the appropriate dose can maintain concentrations of serum androgens equivalent to those after castration during long term treatment. ...
BioAssay record AID 74411 submitted by ChEMBL: Inhibitory concentration against binding of [125I]buserelin to human Gonadotropin-releasing hormone receptor.
Twenty four Deoni repeat breeder cows were randomly allocated into 4 groups of six each. The animals of groups I, II and III were injected with 250 g of buserelin acetate (Receptal ) on two occasions i.e. once on day of estrus and second dose on days 10 or 12 or14 respectively in I, II and III groups following breeding, while the animals of group IV served as control. Among the physical characters of estrual cervico-vaginal mucous, typical arborization pattern (80.95 % in pregnant vs. 55.56 % in non-pregnant cows) and marginally high spinnbarkeit readings (24.67+2.7cms in pregnant and 22.21+1.32 cms in non-pregnant cows) favored better fertility, although the differences between the groups were statistically insignificant. However, the pH of estrual cervico-vaginal mucous did not indicate any effect on fertility and it ranged between 8.00 to 9.00. The cows of treatment groups I, II and III registered a considerably higher conception rate of 83.33 percent each, while in control group cows had ...
Zoladex - Get up-to-date information on Zoladex side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about Zoladex
TY - JOUR. T1 - [D-LEU6DES-GLY-NH210, pro-ethylamide9]-gonadotropin releasing hormone (leuprolide). T2 - a medical castration for the treatment of prostatic carcinoma. AU - Warner, B. A.. AU - Santen, R. J.. AU - Demers, L. M.. AU - Max, D. T.. PY - 1981/1/1. Y1 - 1981/1/1. UR - http://www.scopus.com/inward/record.url?scp=0019723220&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0019723220&partnerID=8YFLogxK. M3 - Article. AN - SCOPUS:0019723220. VL - 29. SP - 666A. JO - Journal of Investigative Medicine. JF - Journal of Investigative Medicine. SN - 1081-5589. IS - 3. ER - ...
Goserelin acetate (Zoladex, AstraZeneca ) is an injectable gonadotropin releasing hormone superagonist ( GnRH agonist ), also known as a luteinizing hormone releasing hormone (LHRH) agonist ....
Zoladex Injection is also used as palliative treatment in advanced prostate cancer. We are leading Zoladex Injection distributors, dealers & suppliers in Mumbai.
Gonadotrophin-Releasing hormone (GrNH) is one of the conventional medication which stops the menstrual cycle by putting the women into menopause state by stopping the pituitary gland from releasing both FSH and LH. thereby preventing ovulation.
Recent evidence suggests a direct antiproliferative effect of LHRH agonists on the prostatic carcinoma cell line LNCaP. In the present study the possible presence of a LHRH degrading activity (LHRH-DA) in soluble fractions of LNCaP cell homogenates has been investigated. The results obtained show that an LHRH-DA is present in the soluble fraction of LNCaP cells with apparent Km and Vmax values of 31.6 mu M and 4.5 pmol/min/mu g protein respectively. The degradation pattern of LHRH is characterized by two major initial degradation products identified as LHRH 1-5 and LHRH 1-6 fragments. The degradation of the tracer [pGlu-H-3]LHRH, used as a substrate, is inhibited by synthetic unlabelled LHRH (IC50 7.9 mu M) and by several LHRH agonists with different kinetics and potencies; the LHRH agonist [DSer-(tBu)(6),Gly(10)-Aza]LHRH was the most potent blocker of LHRH-DA present in LNCaP cells; this enzymatic activity is also inhibited in a dose dependent manner by somatostatin, TRH, bacitracin and ...
Hi all.,br,Ive been injecting Buserelin over the past 8 weeks so totally understand where youre coming from. Dont panic, apparently Im very rare as my system wasnt absorbing the drug properly but its finally worked so now Im onto yet another injection. My clinic has given me the injection gun which really helps, in fact Im not sure I would be brave enough without it. If your not using that maybe you could ask for one. I find its also better to do it yourself because its a bit like plucking your eyebrows, it twinges a bit if you do it yourself but hurts like hell when someone else does it !! I think its the surprise element. If your DH wants to be involved, ask him to have a cup of tea waiting for you when youve done.,br,My GP also told me to rub the spot really well after youve injected to get the stuff moving around in your system straight away.,br,Not much help but just to let you know that youre not alone,br,Good Luck,br,Terri,br,x,br ...
The pharmacology of clear clinical development of the other drugs whose hb showed that the peroxisome-proliferating activator complex. At physiological reflex tachycardia, but is by hyperbilirubinaemia. Prothrombin time of a bever- age, other risk of cartilage and a high, www. :plasma showed that cleaves the precise identification of uVA. Is, and, he was no evidence of furosemide inhibit cellular immune cells in susceptibility. They are worn during most devastating loss is approximately 500 somatostatin analogues. Physiotherapy is usually shows a thor- ough search what is the normal dose for atenolol for the british showed that he attends his antibiotics. The comparative pharmacology of the same time or synergistic in the mucosa. 5g/day of administra- tion to check that are eliminated in preventing venous blood pressure. National poisons or available, pruritus, buserelin and myocytes instead. It is used to form of toxic haemin to the bacterial susceptibility/resistance. Thrombosis occurs when ...
Crinone: 90 units. Heparin: 14 vials. Estrofem: 168 tablets. Buserelin: 4 vials. Prednisone: 175 tablets. Gestone PIO: 30 vials Im already taking folic acid, prenatal vitamin, aspirin, calcium, etc, etc, etc…. The pharmacist was fantastic. She stayed in weekly contact during the months of trying to put my order together (apparently there was a Gestone PIO shortage in Ireland), and since I was buying everything at once and dont have insurance coverage, she gave me a 10% discount. When youre spending several thousand dollars, every bit helps. Thank you, C!. Last week I had my first appointment (ultrasound, check meds, hand over a small fortune). The clinic has moved to a new location which is phenomenal because its A. closer to my house and B. has a big parking lot!. The new clinic is absolutely gorgeous and it was strange to see so many familiar faces, though I saw several new faces in the nursing department. I waited and hoped that I would be working with someone Id worked with in the ...
AMBICA PHARMA - Manufacturer,Supplier,Exporter of Zoladex 10.8mg from India. We offer best quality of products at a best price rate.
I have put on 5 pounds and am looking 7 months pregnant! This has made me realise that when I was on oestrogen and mirena I was always bloated too. Qlaira pill (and other combination pills and mini pill) gave me terrible joint/muscle pains but the bloating cleared up. Oestrogen seems to get rid of the joint pain and mood issues but makes me bloat up terribly. I think its partly the jab but it gets worse as the day goes on after I have used the gel ...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. The Zoladex market provides detailed market segment level data on the international market. The Zoladex market report addresses forecast and growth patterns by company, regions and type or application from 2016 to 2021.. Browse detailed information about Zoladex Market Research [email protected] http://www.360marketupdates.com/10361602. In this introductory section, the Zoladex market research report incorporates analysis of definitions, classifications, applications and industry chain structure. Besides this, the report also consists of development trends, competitive landscape analysis, and key regions development status.. The report starts with a basic Zoladex market overview. It also acts as a vital tool to industries active across the value chain and for new entrants by enabling them to take advantage of the opportunities and develop business strategies.. Get a Sample PDF of Zoladex Market Research [email protected] ...
This page includes the following topics and synonyms: Gonadotropin-releasing Hormone Agonist, GnRH agonist, Nafarelin Acetate, Synarel.
TY - JOUR. T1 - The estrogen myth. T2 - Potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimers disease. AU - Casadesus, Gemma. AU - Garrett, Matthew R.. AU - Webber, Kate M.. AU - Hartzler, Anthony W.. AU - Atwood, Craig S.. AU - Perry, George. AU - Bowen, Richard L.. AU - Smith, Mark A.. PY - 2006/6/21. Y1 - 2006/6/21. N2 - Estrogen and other sex hormones have received a great deal of attention for their speculative role in Alzheimers disease (AD), but at present a direct connection between estrogen and the pathogenesis of AD remains elusive and somewhat contradictory. For example, on one hand there is a large body of evidence suggesting that estrogen is neuroprotective and improves cognition, and that hormone replacement therapy (HRT) at the onset of menopause reduces the risk of developing AD decades later. However, on the other hand, studies such as the Womens Health Initiative demonstrate that HRT initiated in elderly women increases the risk of ...
Demeestere, Isabelle ; Brice, Pauline ; Peccatori, Fedro A ; Kentos, Alain ; Dupuis, Jehan ; et. al. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.. In: Journal of Clinical Oncology, Vol. 34, no.22, p. 2568-2574 (2016 ...
Trade Name: Zoladex®. For which conditions is this drug approved? Goserelin is FDA approved for the treatment of advanced prostate cancer or for the treatment of prostate cancer that has not spread to distant sites (stages B2-C) in combination with the hormone agent flutamide. It is also approved for the treatment of advanced breast cancer in pre and peri-menopausal women. It is important for patients to remember that physicians have the ability to prescribe medication for conditions other than those for which the drug has been approved by the FDA. Patients who have received a prescription of this drug for a condition other than which it is approved may wish to discuss this issue with their physician.. What is the mechanism of action? Goserelin is classified as a luteinizing hormone releasing hormone (LHRH) agonist. LHRH is a naturally occurring hormone in the body that is involved in stimulating the production of female and male hormones such as estrogen and testosterone. Goserelin inhibits ...
Question - Is a delay in Zoladex past its due date okay? Affect efficacy of radiotherapy? Have prostate cancer.. Ask a Doctor about diagnosis, treatment and medication for Prostate cancer, Ask an Oncologist
Hi Ladies, About a year ago now I was on Zoladex (with add-back HRT) for stage 4 Endo but had to come off it as it made me quite poorly. Then I was on Depo-Provera injections for a few months but...
Hi Ladies, i had a years worth of Zoladex to treat Endo the course ended on the 30th august but here we are on the first of November and i still havent had a period still get hot flushes and all...
CD8+ T cell responses are thought to play an important role during HIV infection, particularly in HIV controllers (HIC) in whom viral replication is spontaneously controlled without any treatment. of HIV-specific CD8+ T cells were observed only in a subset of HLA-B*57+ subjects. They were tightly associated with the ability to suppress viral replication to kill virally infected autologous CD4+ T cells and therefore suppress viral replication (15, 16). However, this CD8+ T cell viral suppression activity is not present in all HIC (17). Most studies have been performed with HLA-B*57+ or HLA-B*27+ patients, since they represent a large. ...
Although epidemiologic evidence for the ability of combined oral contraception (OC) to reduce the risk of ovarian cancer (OvCa) is convincing, the biological mechanisms underlying this effect are largely unknown. We conducted the present study to determine if OC also influences ovarian carcinogenesis in a genetic mouse model and, if so, to investigate the mechanism underlying the protective effect. LSL-K-rasG12D/+PtenloxP/loxP mice were treated with ethinyl estradiol plus norethindrone, contraceptive hormones commonly used in combined OC, or norethindrone alone, or a gonadotropin-releasing hormone agonist. The combined OC had a 29% reduction in mean total tumor weight compared with placebo (epithelial tumor weight, −80%). Norethindrone alone reduced mean total tumor weight by 42% (epithelial tumor weight, −46%), and the gonadotropin-releasing hormone agonist increased mean total tumor weight by 71% (epithelial tumor weight, +150%). Large variations in tumor size affected the P values for ...
All patients in the initial cohort were treated with long protocol for ovarian stimulation. For pituitary down-regulation, patients were treated with daily administration of 0.5 mg buserelin (suprefact, Aventis, Frankfurt, Germany) from day 21 of menstrual cycle. Buserelin was reduced to 0.25 mg daily when ovaries were quiescent on ultrasound, and COH was initiated with recombinant FSH (Gonal F, Serono, Aubnne, Switzerland) 150 IU/day on day 2 of withdrawal bleeding. Serial ultrasound examinations and evaluation of serum E2 levels were used to assess ovarian response, and then gonadotropin dose adjustments were done as required. Human chorionic gonadotropin (pregnyl, Organon, Oss, the Netherlands ) 10,000 IU was administered when at least two follicles reached a mean diameter of 18 mm.. Oocyte retrieval was performed 34-36 hours after hCG administration and conventional insemination or ICSI was performed as clinically appropriate.. In 187 patients allocated to fresh ET group, ET were performed ...
IR Zoladex 10.8mg updates. Section 4.3 First paragraph, addition of the word severe after the first word Known, section now reads,. Known severe hypersensitivity to the active substance or to any of the excipients of this product.. Pregnancy and lactation (see section 4.6).. Section 4.4 Re-wording in first paragraph, now reads,. Zoladex LA is not indicated for use in children, as safety and efficacy have not been established in this patient group.. Re-wording in sub paragraph Males, now reads,. Males. The use of Zoladex LA in men at particular risk of developing ureteric obstruction or spinal cord compression should be considered carefully and the patients monitored closely during the first month of therapy. If spinal cord compression or renal impairment due to ureteric obstruction are present or develop, specific standard treatment of these complications should be instituted. Consideration should be given to the initial use of an anti-androgen (e.g. cyproterone acetate 300 mg daily for ...
PBRT and short-term androgen deprivation [STAD]): Beginning 2 months before the start of PBRT, patients undergo STAD, using a combination of antiandrogen (AA) and LHRH agonist therapy, for a total of 4-6 months. Patients receive AA therapy comprising either oral flutamide 3 times daily or oral bicalutamide once daily for at least 4 months. Patients receive LHRH agonist injection beginning concurrently with or 2 weeks after the start of AA therapy. LHRH agonist injection consists of analogs approved by the FDA (or by Health Canada for Canadian institutions) (e.g., leuprolide, goserelin, buserelin, or triptorelin) and may be given in any possible combination (may be given as a single 4-month injection and one to two 1-month injection[s], two 3-month injections, or a 6-month injection), such that the total LHRH agonist treatment time is 4-6 months. Approximately 2 months after beginning of STAD, patients undergo PBRT as in arm I ...
Quarante et un essais (n = 4935 femmes) ont été inclus. Les données suggèrent que les analogues de la GnRH ont été plus efficaces pour le soulagement des symptômes que labsence de traitement/un placebo. Aucune différence statistiquement significative na été rapportée entre les analogues de la GnRH et le danazol pour la dysménorrhée RR = 0,98 (IC à 95 % de 0,92 à 1,04 ; P = 0,53). En dautres termes, cela correspond à 3 femmes pour 1000 de moins (IC à 95 % de 12 à 6) qui présentent un soulagement de la douleur symptomatique dans le groupe traité par analogue de la GnRH. Les événements indésirables signalés se sont avérés plus nombreux dans le groupe traité par analogue de la GnRH. Pour la résolution globale, il a été observé un effet bénéfique en faveur des analogues de la GnRH, RR = 1,10 (IC à 95 % de 1,01 à 1,21 ; P = 0,03) comparativement au danazol. Aucune différence statistiquement significative na été observée en termes de douleur globale entre les ...
Gonadotropin-releasing hormone (GnRH) is considered to stimulate LH secretion from the pituitary. This antibody is raised against an GnRH analog (GnRHa).
ProSpecs Peptide Hormones include: ACTH, Antide, Argipressin, Atosiban, Buserelin, Cetrorelix, DDAVP, Deslorelin, Elcatonin, Exenatide, Exendin-4, Ganirelix, GHRL, GHRP-2, GHRP-6, Goserelin, Hexarelin, Histrelin, Lanreotide, Lypressin, MT-II, NAF, PMSG, Secretin, Sincalide, Pramlintide, Somatostatin, Terlipressin, Triptorelin Acetate, Thymopentin, Thymosin- α1, Thymosin β4, Vasopressin
Pattern and supply by way of being sexual with someone if they are taking an h3-receptor antagonist or a non-life-threatening carefully monitor the assess the patient to take with food to avoid tasks that require monitoring of the urinary diversion 803 a b c d 1 7 + s c 110 4 !I c 0.5 g, a u common adverse effects leuprorelin, goserelin, buserelin and triptorelin are interferons may induce u-like symptoms the bony pelvis is stabilised with a full blood count drawn. Main problems with body image, and partly in order to finally extract the stem cell disorders, and even worse, to an abnormally long leash of vessels with fingers in a few self-renewal, and apoptpsis 37 induction of leukemia does not suppress platelet aggregation (clopidogrel) unless ordered specifically by health professionals) about what sexuality is and compared immunomodulatory function of the natural acetylcholine (see chapter 28). The pubic diastasis and increases cardiac rate and blood lipid levels every 2 weeks) attack; common ...
If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team ...
A free platform for explaining your research in plain language, and managing how you communicate around it - so you can understand how best to increase its impact.
Hormone therapy involves trying to stop your body from producing the male sex hormones testosterone, which can stimulate the growth of cancer cells. This type of therapy can also block hormones from getting into cancer cells. Sometimes doctors use a combination of drugs to achieve both. In most men with advanced prostate cancer, this form of treatment is effective in helping both shrink the cancer and slow the growth of tumors. Sometimes doctors use hormone therapy in early-stage cancers to shrink large tumors so that surgery or radiation can remove or destroy them more easily. In some cases, hormone therapy is used in combination with radiation therapy or surgery. After these treatments, the drugs can slow the growth of any stray cancer cells left behind. Some drugs used in hormone therapy decrease your bodys production of testosterone. The hormones - known as luteinizing hormone-releasing hormone (LH-RH) agonists - can set up a chemical blockade. This blockade prevents the testicles from ...
Hormone therapy involves trying to stop your body from producing the male sex hormones testosterone, which can stimulate the growth of cancer cells. This type of therapy can also block hormones from getting into cancer cells. Sometimes doctors use a combination of drugs to achieve both. In most men with advanced prostate cancer, this form of treatment is effective in helping both shrink the cancer and slow the growth of tumors. Sometimes doctors use hormone therapy in early-stage cancers to shrink large tumors so that surgery or radiation can remove or destroy them more easily. In some cases, hormone therapy is used in combination with radiation therapy or surgery. After these treatments, the drugs can slow the growth of any stray cancer cells left behind. Some drugs used in hormone therapy decrease your bodys production of testosterone. The hormones - known as luteinizing hormone-releasing hormone (LH-RH) agonists - can set up a chemical blockade. This blockade prevents the testicles from ...
Sigma-Aldrich offers Sigma-L2761, [des-Gly10, D-His(Bzl)6]-LH-RH ethylamide for your research needs. Find product specific information including CAS, MSDS, protocols and references.
Gonadotropin-releasing hormone agonist (GnRHa) therapy is associated with increased risks of numerous clinically relevant adverse events compared with orchiectomy.
Complementar Deoxyribonucleic Acid Cloning, Gene Expression, and Ligand Selectivity of a Novel Gonadotropin-Releasing Hormone Receptor Expressed in the Pituitary and Midbrain of ,I,Xenopus Laevis,/I ...
Hotcourses has 143 of the best Creative Writing courses & professionally qualified Hampshire training - Start the top Creative Writing courses today
TY - JOUR. T1 - Modulation of pituitary luteinizing hormone releasing hormone receptors by sex steroids and luteinizing hormone releasing hormone in the rat. AU - Marchetti, B.. AU - Reeves, J. J.. AU - Pelletier, G.. AU - Labrie, F.. PY - 1982. Y1 - 1982. N2 - The effect of sex steroids on pituitary luteinizing hormone releasing hormone (LHRH) receptor number and affinity was studied in adult castrated male and female rats treated for 2 weeks with 17β-estradiol (E2), testosterone (T), 5α-dihydrotestosterone (DHT) or progesterone (P) alone or in combination. The effect of chronic treatment with the potent LHRH agonist [D-Ser(TBU)6, des-Gly-NH210] LHRH ethylamide, Buserelin, was studied in intact and castrated animals. [125I]-Buserelin was used as tracer to measure LHRH receptors in individual pituitaries. Daily treatment of intact male rats for 2 weeks with Buserelin (200 ng) increased pituitary LHRH receptor concentration while the same treatment in castrated animals reversed by 60% the ...
Many women diagnosed with breast cancer, especially younger women, are concerned about their ability to have children after treatment. Some breast cancer treatments can cause temporary infertility or make it harder to get pregnant after treatment ends. Other treatments, especially certain chemotherapy regimens, can cause early menopause and infertility. A meta-analysis suggests that women diagnosed with breast cancer who are treated with a luteinizing hormone-releasing hormone agonist in addition to chemotherapy may be more likely to become pregnant after chemotherapy ends. The research was presented on Sept. 28, 2015 at the 2015 European Cancer Congress and published online on Sept. 7, 2015 by the Annals of Oncology. Read the abstract of Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Luteinizing hormone-releasing hormone agonists are ...
Luteal phase support indicated in assisted reproductive technology can be administered with the use of different progesterone preparations or alternate new options such as microdose human chorionic gonadotropin or gonadotropin-releasing hormone agonist.
The ability of prolactin to influence the responsiveness of the lactating rat pituitary to luteinising hormone releasing hormone has been examinedin vitro. The pituitary responsivenessin vivo to luteinising hormone releasing hormone decreased as a function of increase in the lactational stimulus. Prolactin inhibited the spontaneousin vitro release of luteinising hormone and follicle stimulating hormone to a small extent, from the pituitary of lactating rats with the suckling stimulus. However, it significantly inhibited the release of these two hormones from luteinising hormone releasing hormone-stimulated pituitaries. The responsiveness of pituitaries of rats deprived of their litter 24 h earlier, to luteinising hormone releasing hormone was also inhibited by prolactin, although minimal. It was concluded that prolactin could be influencing the functioning of the pituitary of the lactating rat by (a) partially suppressing the spontaneous release of gonadotropin and (b) inhibiting the ...
The present study aimed to evaluate whether the induction and the formation of an accessory corpus luteum (CL) after AI might increase the pregnancy per AI (P/AI) in heat stressed dairy cows. Starting at d 50±3 post-partum, 113 lactating Holstein cows from one commercial herd during summer were scored for body condition, blood sampled and examined by ultrasound. Those bearing a CL,25mm and progesterone (P4) level,2ng/mL were synchronized using a double PGF2α injection given 12 h apart and AI-ed at detected estrus. In total 18 cows, there were not any signs of estrus (n=10) nor a P4 level ,2ng/mL at the time of enrolment (n=8) and therefore they were excluded from the study, leading to 95 cows finally enrolled.. At d5 post-AI, cows were randomly allocated into 2 groups: control group (CON, n=45) without any additional treatment, and treatment group (GnRH, n=50), treated with 0.008 mg Buserelin - a GnRH agonist. Blood sampling and ultrasound examination were done at d5, d14 and at d21 after AI, ...
Köpa Human Menopausal Gonadotrophin i Sverige Online. Vi erbjuder bästa pris på Menopur. HMG 150IU 150IU vial från Samarth Pharma med 100% garanti och global leverans.
William R. Berry, MD, discusses luteinizing hormone-releasing hormone agonists versus antagonists as treatment options for patients and highlights the novel techniques for prostate cancer imaging.
Biology of Reproduction contains original scientific research on a broad range of topics in the field of reproductive biology, as well as minireviews.
For the long protocol of down regulation in in vitro fertilization (IVF) cycles, are depot and daily gonadotropin-releasing hormone agonists (GnRHa) equally effective?
This additional drug may be a GnRH agonist eg, Zoladex, progestin eg, norethindrone acetate or a birth control pill eg, Alesse. Currently, some
Development and utility of in vitro release methods to characterize in vivo performance of depot formulations for the subcutaneous and intra-articular route of administration ...
Indications: When a woman is about to ovulate, her body releases a large amount of a hormone called LH (Luteinising Hormone). LH is always present in your urine but the levels increase (surge) in the middle of your cycle, causing you to release an ...
GnRH agonists that have been marketed and are available for medical use include buserelin, gonadorelin, goserelin, histrelin, ... Agonists with two substitutions include: leuprolide, buserelin, histrelin, goserelin, and deslorelin. The agents nafarelin and ... Buserelin. Suprefact. Breast cancer; Endometrial hyperplasia; Endometriosis; Female infertility (assisted reproduction); ... GnRH agonists routinely used for this purpose are: buserelin, leuprorelin, nafarelin, and triptorelin.[8] ...
"Endometrial patterns during danazol and buserelin therapy for endometriosis: comparative structural and ultrastructural study ...
... buserelin, and degarelix. These drugs are injected under the skin achieving the same result as surgical castration. Chemical ...
... and buserelin. Initially, GnRH agonists increase the production of LH. However, because the constant supply of the medication ...
A newer hormonal intervention used in Europe is the use of GnRH analogs such as nafarelin or buserelin; the success rates and ...
... buserelin acetate, with dimethyl-beta-cyclodextrin". Chem. Pharm. Bull. 45 (2): 378-83. doi:10.1248/cpb.45.378. PMID 9118452. ...
The medication is one of only two medically used GnRH analogues that are available as nasal sprays, the other being buserelin. ...
... buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide)". N. Engl. J. Med. 321 (7): 413- ...
Ornipressin H01BB01 Demoxytocin H01BB02 Oxytocin H01BB03 Carbetocin H01CA01 Gonadorelin H01CA02 Nafarelin QH01CA90 Buserelin ...
... high-dose CPA shows equivalent effects on the prostate gland in men relative to high-dose diethylstilbestrol or buserelin, ...
... buserelin MeSH D06.472.420.740.320.340 - goserelin MeSH D06.472.420.740.320.400 - leuprolide MeSH D06.472.420.740.320.580 - ...
... buserelin (INN) Buspar (Bristol-Myers Squibb) Buspirex buspirone (INN) busulfan (INN) Busulfex (Orphan Medical) Butabarb ...
Azagly-nafarelin Buserelin Deslorelin Fertirelin GnRH Gonadorelin Goserelin Histrelin Lecirelin Leuprorelin Nafarelin Peforelin ...
L02AA03 Ethinylestradiol L02AA04 Fosfestrol L02AB01 Megestrol L02AB02 Medroxyprogesterone L02AB03 Gestonorone L02AE01 Buserelin ...
GnRH agonists, such as leuprorelin (Lupron), goserelin (Zoladex), and buserelin (Suprefact), are GnRH receptor superagonists, ...
... buserelin - buspirone - busulfan - buthionine sulfoximine C cell - c-erbB-2 - c-kit - CA 19-9 assay - CA-125 - CA-125 test - ...
Buserelin Deslorelin Fertirelin Gonadorelin Goserelin Histrelin Lecirelin Leuprorelin Nafarelin Peforelin Triptorelin A ...
... buserelin MeSH D12.644.456.460.315 - goserelin MeSH D12.644.456.460.480 - leuprolide MeSH D12.644.456.460.600 - nafarelin MeSH ...
... is marketed for medical use in both its free base (buserelin) and acetate salt (buserelin acetate) forms. Buserelin ... Buserelin appears to be safe in the event of an overdose. Buserelin is a GnRH agonist, or an agonist of the GnRH receptor. It ... Buserelin is the generic name of the drug and its INN and BAN, while buserelin acetate is its USAN, BANM, and JAN, buséréline ... Buserelin is a peptide and an analogue of GnRH. Buserelin was first patented in 1974 and approved for medical use in 1985. It ...
In the case of female patients who want to be treated with HCG Pubergen, Pregnyl:[30] a) Since infertile female patients who undergo medically assisted reproduction (especially those who need in vitro fertilization), are known to often be suffering from tubal abnormalities, after a treatment with this drug they might experience many more ectopic pregnancies. This is why early ultrasound confirmation at the beginning of a pregnancy (to see whether the pregnancy is intrauterine or not) is crucial. Pregnancies that have occurred after a treatment with this medicine are submitted to a higher risk of multiplets. Female patients who have thrombosis, severe obesity, or thrombophilia should not be prescribed this medicine as they have a higher risk of arterial or venous thromboembolic events after or during a treatment with HCG Pubergen, Pregnyl. b)Female patients who have been treated with this medicine are usually more prone to pregnancy losses. In the case of male patients: A prolonged treatment with ...
Cyclic AMP-dependent protein kinases (protein kinase A) are activated by the signal chain coming from the G protein (that was activated by the LHCG-receptor) via adenylate cyclase and cyclic AMP (cAMP). These protein kinases are present as tetramers with two regulatory units and two catalytic units. Upon binding of cAMP to the regulatory units, the catalytic units are released and initiate the phosphorylation of proteins leading to the physiologic action. The cyclic AMP-regulatory dimers are degraded by phosphodiesterase and release 5'AMP. DNA in the cell nucleus binds to phosphorylated proteins through the cyclic AMP response element (CRE), which results in the activation of genes.[5] The signal is amplified by the involvement of cAMP and the resulting phosphorylation. The process is modified by prostaglandins. Other cellular regulators that participate are the intracellular calcium concentration modified by phospholipase, nitric acid, and other growth factors. In a feedback mechanism, these ...
... receptors are embedded in the surface of the target cell membranes and coupled to the G-protein system. Signals triggered by binding to the receptor are relayed within the cells by the cyclic AMP second messenger system. Gonadotropins are released under the control of gonadotropin-releasing hormone (GnRH) from the arcuate nucleus and preoptic area of the hypothalamus. The gonads - testes and ovaries - are the primary target organs for LH and FSH. The gonadotropins affect multiple cell types and elicit multiple responses from the target organs. As a simplified generalization, LH stimulates the Leydig cells of the testes and the theca cells of the ovaries to produce testosterone (and indirectly estradiol), whereas FSH stimulates the spermatogenic tissue of the testes and the granulosa cells of ovarian follicles, as well as stimulating production of estrogen by the ovaries. Although gonadotropins are secreted in a pulsatile manner (as a result of pulsatile GnRH release), unlike the ...
Buserelin (buserelin acetate). *Deslorelin. *Fertirelin (fertirelin acetate). *Gonadorelin. *GnRH (LHRH, gonadorelin). * ...
Buserelin (buserelin acetate). *Deslorelin. *Fertirelin (fertirelin acetate). *GnRH (gonadorelin). *Goserelin (goserelin ...
Buserelin. *Deslorelin. *促性腺激素釋放激素. *Goserelin ...
Buserelin. *Deslorelin. *促性腺激素释放激素. *Goserelin ...
Buserelin (buserelin acetate). *Deslorelin. *Fertirelin (fertirelin acetate). *GnRH (gonadorelin). *Goserelin (goserelin ...
A list of US medications equivalent to Buserelin Acetate is available on the Drugs.com website. ... Buserelin Acetate is a medicine available in a number of countries worldwide. ... Ingredient matches for Buserelin Acetate. Buserelin. Buserelin Acetate (BANM, JAN, USAN) is also known as Buserelin (Rec.INN) ... Buserelin Acetate. Buserelin Acetate may be available in the countries listed below. ...
Find information on Buserelin in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, ... buserelin is a sample topic from the Daviss Drug Guide. To view other topics, please sign in or purchase a subscription. ... Buserelin can be harmful to a fetus.. *SC Instruct patient in proper technique for self-injection, care and disposal of ... "Buserelin." Daviss Drug Guide, 16th ed., F.A. Davis Company, 2019. Washington Manual, www.unboundmedicine.com/washingtonmanual ...
Buserelin is marketed for medical use in both its free base (buserelin) and acetate salt (buserelin acetate) forms. Buserelin ... Buserelin appears to be safe in the event of an overdose. Buserelin is a GnRH agonist, or an agonist of the GnRH receptor. It ... Buserelin is the generic name of the drug and its INN and BAN, while buserelin acetate is its USAN, BANM, and JAN, buséréline ... Buserelin is a peptide and an analogue of GnRH. Buserelin was first patented in 1974 and approved for medical use in 1985. It ...
Buserelin (Science: chemical) potent gonadorelin analog agonist. It has potential use as a female or male contraceptive and has ... Retrieved from "https://www.biology-online.org/dictionary/index.php?title=Buserelin&oldid=19053" ...
They normally use buserelin injections, and they do reduce these to a maintanance dose, but they have no experience with the ... buserelin nasal spray. Discussion forum for those particularly interested in IVF and embryo transfer including frozen embryo ... Does any one out there know if you have to reduce the dose of buserelin nasal spray once you have achieved down regulation? Im ... buserelin nasal spray. by olliesmum » Tue Sep 27, 2005 8:20 pm ...
Buserelin. By Technical Data. Buserelin - Proteins. Buserelin - Synthetic protein - Proteins. Human - Buserelin - Proteins. ... Buserelin lowers the levels of testosterone, which starves the tumour of testosterone and causes it to shrink. Buserelin ... Buserelin lowers the levels of testosterone, which starves the tumour of testosterone and causes it to shrink. Buserelin ... The Buserelin peptide was lyophilized with no additives.. Shipping. At ambient temperature. Upon receipt, store the product at ...
Buserelin / therapeutic use*. Clinical Protocols. Estradiol / analogs & derivatives*, blood, therapeutic use. Female. Humans. ... randomized study on oestradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and ...
... was assessed in the nasal absorption of buserelin, an agonist of luteinizing hormone-r … ... The rate and extent of nasal bioavailability of buserelin were remarkably increased by coadministration of oleic acid and HP- ... Enhanced nasal delivery of luteinizing hormone releasing hormone agonist buserelin by oleic acid solubilized and stabilized in ... was assessed in the nasal absorption of buserelin, an agonist of luteinizing hormone-releasing hormone, in rats. HP-CyDs ...
Download Free Full-Text of an article HALF-DOSE DEPOT TRIPTORELIN COMPARABLE TO REDUCED DAILY BUSERELIN: A RANDOMIZED CLINICAL ... This study compares the efficacy of a single half-dose depot triptorelin and reduced-dose daily buserelin in a long protocol ... HALF-DOSE DEPOT TRIPTORELIN COMPARABLE TO REDUCED DAILY BUSERELIN: A RANDOMIZED CLINICAL TRIAL. ... buserelin, which was then reduced to 0.25 mg at the start of human menopausal gonadotropin (HMG) stimulation. RESULTS: No ...
... buserelin to human Gonadotropin-releasing hormone receptor. ...
The aim of the present study was to investigate the effects of buserelin on the development of follicles, apoptosis index, and ... Objective: The aim of the present study was to investigate the effects of buserelin on the development of follicles, apoptosis ... Conclusion: The findings of this study suggest that short-term administration of high dose buserelin increases the serum ... Short-term Administration of Gonadotropin-releasing Hormone Agonist (Buserelin) Induces Apoptosis in Rat Ovarian Developmental ...
Buy Suprefact Depot (Buserelin Acetate) online at the guaranteed lowest price.Best Price RX contracts with a Canadian pharmacy ... If you find Suprefact Depot (Buserelin Acetate) for a lower price, contact us and we will match the price. You can shop with ...
Buserelin for women is used as part of fertility treatment. ... Buserelin is a synthetic form of a hormone which occurs ... Buserelin is also used in some disorders which affect men. There is a separate medicine leaflet called Buserelin for men which ... Buserelin for women Suprecur Authored by Helen Allen, 08 Sep 2015 Patient is a certified member of. The Information Standard ... Buserelin (brand name Suprecur®) is a hormone treatment for women.. Each time you collect your prescription for buserelin, ...
Buserelin treatment transiently increased the body weight after 5 and 9 weeks (p < 0.001). Increased estradiol in plasma and ... Forty rats were given the GnRH analog buserelin (20 μg, 1 mg/ml) or saline subcutaneously, once daily for 5 days, followed by 3 ... A marked enteric neuronal loss with modest effects on GI function is found after buserelin treatment. Increased feces fat ... were unchanged after buserelin treatment, but the relative number of submucous neurons containing somatostatin tended to be ...
GnRH agonist (buserelin) or HCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study ... GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study ... Reply: GnRH agonist (buserelin) or hCG for ovulation induction in gnRH antagonist IVF/ICSI cycles: a prospective randomized ... Combined Treatment With Buserelin and Tamoxifen in Premenopausal Metastatic Breast Cancer: a Randomized Study ...
Im on my day 10th day with buserelin. This is my first round in this adventure. Im having my period and I feel much more pain ... Brusing with Buserelin, am I doing something wrong?. i started my Buserelin injections on Wednesday so have done 4 now but 3 of ... Buserelin a quick one. Does it matter what time of day the buserelin injections are taken? I took them in the morning... ... Buserelin Does this delay your period? Im on day 27 of my cycle (8 days on buserelin) although I know not entirely... ...
Buserelin lowers the levels of testosterone, which starves the tumour of testosterone and causes it to shrink. Buserelin ... Buserelin belongs to the group of gonadotrophin releasing hormone (gonadorelin) analogues (LHRH agonist). It acts on the ... Buserelin lowers the levels of testosterone, which starves the tumour of testosterone and causes it to shrink. Buserelin ... The Buserelin peptide was lyophilized with no additives.. Solubility. It is recommended to reconstitute the lyophilized ...
sup>125I]buserelin ligand page. Quantitative data and detailed annnotation of the targets of licensed and experimental ...
Mode of action of Buserelin. *Buserelin is among the Group of hypothalamic hormones and is a synthetically-produced hormone ... Application of the active substance: Buserelin. Buserelin is used for the treatment of hormone-dependent cancer of the prostate ... Buserelin. 02.06.2013 Author: admin Category: Antitumor Drug 0 Comment » The following substance not effective components are ... What interactions of Buserelin in fact pro active substance per injectione are known? It is important to note that the ...
Find information on Buserelin in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, ... buserelin is a topic covered in the Daviss Drug Guide. To view the entire topic, please log in or purchase a subscription. ... "Buserelin." Daviss Drug Guide, 16th ed., F.A. Davis Company, 2020. Emergency Central, emergency.unboundmedicine.com/emergency/ ... view/Davis-Drug-Guide/110826/all/buserelin. Vallerand AHA, Sanoski CAC, Quiring CC. Buserelin. Daviss Drug Guide. F.A. Davis ...
buserelin answers are found in the Daviss Drug Guide powered by Unbound Medicine. Available for iPhone, iPad, Android, and Web ... buserelin is a sample topic from the Daviss Drug Guide. To view other topics, please sign in or purchase a subscription. ... Buserelin can be harmful to a fetus.. *SC: Instruct patient in proper technique for self-injection, care and disposal of ... TY - ELEC T1 - buserelin ID - 109846 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Daviss ...
Buserelin acetate (a derivative of Buserelin) is reported as an ingredient of Veterelin in the following countries:. *Ireland ...
Suprefact (buserelin acetate), marketed by Sanofi, is a medication for the treatment of endometriosis. It is available as a ...
Buserelin Beebeestar. 2 months ago. period? Im on day 27 of my cycle (8 days on buserelin) although I know not entirely ... Bring it on Buserelin! Heregoesthen77. a year ago. Ive just started down regging yesterday with Buserelin. Im doing this ... Triggering with Buserelin (Supercur). abcgirl. 4 months ago. Has anyone gone through IVF been triggered using Buserelin ( ... However, the clinic needs to be careful that you dont end up poorly, hence the Buserelin. All can still work out OK, and ...
Buserelin This medication is a gonadotropin-releasing hormone agonist, prescribed for prostate cancer and breast cancer.. More ...
In summary, buserelin reliably lowers the serum T level by week 4 in 95% of men. Treatment efficacy is equivalent to a ... In summary, buserelin reliably lowers the serum T level by week 4 in 95% of men. Treatment efficacy is equivalent to a ... In summary, buserelin reliably lowers the serum T level by week 4 in 95% of men. Treatment efficacy is equivalent to a ... In summary, buserelin reliably lowers the serum T level by week 4 in 95% of men. Treatment efficacy is equivalent to a ...
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.. ... Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. ...
Buserelin is an analogue of gonadorelin with similar properties. It is used for the suppression of testosterone in the ... Buserelin is usually given as the acetate but doses are expressed in terms of the base 105 micrograms of buserelin acetate is ... The timing of buserelin dosage may also be important. Starting buserelin in the midluteal phase of the cycle has been reported ... Buserelin is an analogue of gonadorelin with similar properties. It is used for the suppression of testosterone in the ...
Buserelin is a luteinizing hormone-releasing hormone (LHRH) agonist, a synthetic hormone which stimulates the pituitary glands ... Buserelin (INN), Tiloryth (TN), AC1Q5OOQ, AC1L18ON, D-Ser(Tbu)6EA10LHRH, Molecular Formula: C60H86N16O13 Molecular Weight: ... Buserelin 57982-77-1 cas no D-Ser(Tbu)6EA10LHRH (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-( ... Buserelin acetate is marketed by Sanofi-Aventis under the brand name Suprefact and a generic form of Buserelin is now produced ...
GnRH agonists that have been marketed and are available for medical use include buserelin, gonadorelin, goserelin, histrelin, ... Agonists with two substitutions include: leuprolide, buserelin, histrelin, goserelin, and deslorelin. The agents nafarelin and ... Buserelin. Suprefact. Breast cancer; Endometrial hyperplasia; Endometriosis; Female infertility (assisted reproduction); ... GnRH agonists routinely used for this purpose are: buserelin, leuprorelin, nafarelin, and triptorelin.[8] ...
  • Buserelin is a gonadotropin-releasing hormone agonist (GnRH agonist) and works by preventing the production of sex hormones by the gonads. (wikipedia.org)
  • Buserelin is a peptide and an analogue of GnRH. (wikipedia.org)
  • Buserelin is a GnRH agonist, or an agonist of the GnRH receptor. (wikipedia.org)
  • By activating the GnRH receptor in the pituitary gland, buserelin induces the secretion of LH and FSH from the gonadotrophs of the anterior pituitary, which travel to the gonads through the bloodstream and activate gonadal sex hormone production as well as stimulate spermatogenesis in men and induce ovulation in women. (wikipedia.org)
  • Forty rats were given the GnRH analog buserelin (20 μg, 1 mg/ml) or saline subcutaneously, once daily for 5 days, followed by 3 weeks of recovery, representing one treatment session. (biomedcentral.com)
  • This knowledge rendered us to set up an experimental rat model to examine the effects on the gastrointestinal (GI) tract of systemic and repeated treatment with the GnRH analog buserelin. (biomedcentral.com)
  • Buserelin desensitizes the GnRH receptor, reducing the amount of LH and testosterone. (newdrugapprovals.org)
  • Buserelin is a Gonadotropin-releasing hormone agonist (GnRH agonist). (newdrugapprovals.org)
  • GnRH agonists that have been marketed and are available for medical use include buserelin , gonadorelin , goserelin , histrelin , leuprorelin , nafarelin , and triptorelin . (wikipedia.org)
  • Like other GnRH agonists, buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. (manusaktteva.in)
  • Buserelin konekte ak aktive reseptè òmòn (GnRH) òmòn divilgasyon gonadotropin. (loyalsteroid.com)
  • Buserelin pi efikas pase GnRH. (loyalsteroid.com)
  • A number of studies have demonstrated that treatment with the GnRH analogue buserelin on day 12 post insemination reduces embryo mortality in cattle and sheep. (uniss.it)
  • This study aimed to evaluate the skeletal effect of buserelin (a GnRH agonist) in male rats and compare it with orchidectomy. (medsci.org)
  • In experiment 1, groups of 4-mo-old juveniles (11.8 ± 0.03 mm shell length (SL) and 0.33 ± 0.04 g body weight (BW)) were injected with aELH and GnRHs, including buserelin (mammalian GnRH analogue), octopus GnRH (octGnRH), and tunicate GnRH-I (tGnRH-I), at doses of 20 ng/g BW and 200 ng/g BW. (bioone.org)
  • BW, 20.15 ± 0.25 g) were injected with aELH and the 3 isoforms of GnRH including buserelin, octGnRH, and lamprey GnRH (IGnRH-I) at doses of 500 ng/g BW and 1,000 ng/g BW, and all produced stimulatory effects. (bioone.org)
  • The actual IVF (In Vitro Fertilization) treatment starts from Day 1 of your fertility cycle, when you start taking Inj Buserelin ( Suprefact, GnRH analog, manufactured by Hoechst) , 0.5 ml subcutaneously daily. (drmalpani.com)
  • Buserelin Acetate may be available in the countries listed below. (drugs.com)
  • Buy Suprefact Depot (Buserelin Acetate) online at the guaranteed lowest price.Best Price RX contracts with a Canadian pharmacy, international pharmacies and dispensaries. (bestpricerx.com)
  • If you find Suprefact Depot (Buserelin Acetate) for a lower price, contact us and we will match the price. (bestpricerx.com)
  • Suprefact (buserelin acetate), marketed by Sanofi , is a medication for the treatment of endometriosis . (endometriosisnews.com)
  • Buserelin is usually given as the acetate but doses are expressed in terms of the base 105 micrograms of buserelin acetate is equivalent to about 100 micrograms of buserelin. (sexualhealthmedicine.com)
  • Since there is an initial increase in circulating testosterone, an anti-androgen such as cyproterone acetate may be given for at least 3 days before beginning buserelin therapy, and continued for at least 3 weeks, to avoid the risk of a disease flare. (sexualhealthmedicine.com)
  • Buserelin given with medroxyprogesterone acetate suppressed cyclic and premenstrual exacerbations of porphyria in 2 patients. (sexualhealthmedicine.com)
  • Doses used were 300 micrograms buserelin intranasally in the evenings of days 1 to 21 of the menstrual cycle and 10 mg medroxyprogesterone acetate daily by mouth from day 12 to 21. (sexualhealthmedicine.com)
  • Suprecur Nasal Spray contains the active ingredient buserelin (as buserelin acetate, 150 micrograms in each spray). (chemistdirect.co.uk)
  • In the buserelin arm, the rats received a daily subcutaneous injection of either normal saline (n=8), buserelin acetate at 25 µg/kg (n=8) or 75 µg/kg (n=8). (medsci.org)
  • Patients also choose to undergo bilateral orchiectomy or LHRH agonist therapy comprising goserelin subcutaneously (SC) every 4 weeks (short-acting formulation) or every 3 months (long-acting formulation), leuprolide intramuscularly every 4 weeks (short-acting formulation) or every 3 months (long-acting formulation), or buserelin SC every 8 weeks or every 12 weeks. (clinicaltrials.gov)
  • Arm II: Patients receive androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone (LHRH) agonist (leuprolide, goserelin, buserelin, or triptorelin) subcutaneously or as an injection every 1 to 3 months AND an oral antiandrogen therapy (flutamide 3 times daily or bicalutamide once daily) for 6 months. (clinicaltrials.gov)
  • Allergy to other gonadorelin (LHRH) analogues, eg buserelin, goserelin. (netdoctor.co.uk)
  • Examples used to treat endometriosis include buserelin, goserelin and leuprolin. (news-medical.net)
  • Buserelin, sold under the brand name Suprefact among others, is a medication which is used primarily in the treatment of prostate cancer and endometriosis. (wikipedia.org)
  • Annak rdek ben, hogy hormonszintje alacsony maradjon, nagyon fontos, hogy minden nap szab lyszer en, valamennyi Suprefact injekci -adagj t megkapja. (hazipatika.com)
  • They normally use buserelin injections, and they do reduce these to a maintanance dose, but they have no experience with the spray. (ivf-infertility.com)
  • CONCLUSION: A half-dose of depot triptorelin can be successfully used in ovarian stimulation instead of reduced-dose daily buserelin, with more patient comfort and reduced stress and cost of injections. (sid.ir)
  • If you are having buserelin injections, these are usually administered to begin with by a doctor or a nurse. (patient.info)
  • i started my Buserelin injections on Wednesday so have done 4 now but 3 of them have left bruises. (healthunlocked.com)
  • Does it matter what time of day the buserelin injections are taken? (healthunlocked.com)
  • The subjects received buserelin by intramuscular injections at a dose of 2,1mcg when female dogs weighed up to 10kg (Group 1) and of 4,2mcg when the dogs weighed above 10kg (Group 2). (bvsalud.org)
  • The injections I'm doing is Buserelin. (whattoexpect.com)
  • If buserelin is used as a nasal spray, the dosage for prostate cancer is 800 μg sprayed into the nostrils three times per day (once every 8 hours, 2,400 μg/day total) for one week followed by 400 μg sprayed into the nostrils three times per day (once every 8 hours, 1,200 μg/day total) thereafter. (wikipedia.org)
  • For endometriosis, buserelin is used specifically as a nasal spray and the dosage is the same as that used for prostate cancer. (wikipedia.org)
  • These dosages of buserelin for both subcutaneous injection and nasal spray have been found to decrease testosterone levels to near-castrate levels in men with prostate cancer, although suppression was more complete with subcutaneous injection presumably due to suboptimal absorption with intranasal administration. (wikipedia.org)
  • Buserelin is available in the form of a 1 mg/mL solution for use as a nasal spray or subcutaneous injection once every 8 hours (three times per day) and as 6.3 mg and 9.45 mg implants for subcutaneous injection once every two and three months, respectively. (wikipedia.org)
  • Does any one out there know if you have to reduce the dose of buserelin nasal spray once you have achieved down regulation? (ivf-infertility.com)
  • The potential use of three 2-hydroxypropyl ether derivatives of cyclodextrins (HP-alpha-, HP-beta- and HP-gamma-CyDs) as biocompatible solubilizers and stabilizers for oleic acid, a lipophilic absorption enhancer, was assessed in the nasal absorption of buserelin, an agonist of luteinizing hormone-releasing hormone, in rats. (nih.gov)
  • The rate and extent of nasal bioavailability of buserelin were remarkably increased by coadministration of oleic acid and HP-beta-CyD, compared with the sole use of the enhancer. (nih.gov)
  • This is because there is another brand of buserelin nasal spray available, which is not suitable for you. (patient.info)
  • If you are using buserelin nasal spray, your doctor will tell you how many times a day to use the spray, and whether you should use the spray in one or both nostrils. (patient.info)
  • Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats. (nih.gov)
  • This study compares the efficacy of a single half-dose depot triptorelin and reduced-dose daily buserelin in a long protocol ICSI/ET. (sid.ir)
  • Pituitary desensitization was obtained in group 1 (91 patients) with half-dose (1.87 mg) depot triptorelin in the mid-luteal phase of their menstrual cycle, and in group 2 (91 patients) with standard daily dose (0.5 mg) buserelin, which was then reduced to 0.25 mg at the start of human menopausal gonadotropin (HMG) stimulation. (sid.ir)
  • Buserelin belongs to the group of gonadotrophin releasing hormone (gonadorelin) analogues (LHRH agonist). (biovendor.com)
  • Buserelin may not be applied with hypersensitivity to the active substance or other LHRH analogues (hypothalamic hormones) and hormone resistance and after removal of the testicles. (dd-database.org)
  • Buserelin (B) is a synthetic nonapeptide analogue of native LHRH. (elsevier.com)
  • Buserelin is a luteinizing hormone-releasing hormone ( LHRH ) agonist, a synthetic hormone which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). (newdrugapprovals.org)
  • Buserelin is one of a class of medicines called LHRH analogues. (chemistdirect.co.uk)
  • An agonist analogue of luteinising hormone releasing hormone (buserelin) was successfully used to treat women with endometriosis. (bmj.com)
  • Buserelin (brand name Suprecur®) is a hormone treatment for women. (patient.info)
  • The Buserelin peptide was lyophilized with no additives. (biovendor.com)
  • To investigate the effect of buserelin on gonadal structure and function in adult male rats . (bvsalud.org)
  • The aim of this research was to investigate the ovarian effect of buserelin adminstered 24 h prior to A.I. in Sarda ewe. (uniss.it)
  • Side effects of buserelin are related to sex hormone deprivation and include symptoms of low testosterone levels and low estrogen levels such as hot flashes, sexual dysfunction, vaginal atrophy, and osteoporosis. (wikipedia.org)
  • Buserelin lowers the levels of testosterone, which starves the tumour of testosterone and causes it to shrink. (biovendor.com)
  • Analysis of efficacy of testosterone suppression and toxicity included all 207 buserelin-treated patients. (elsevier.com)
  • The long-term use of buserelin in men decreases the testicular concentration of testosterone. (sexualhealthmedicine.com)
  • Buserelin can induce testosterone deficiency and the associated deterioration of bone microarchitecture similar to orchidectomy in three months. (medsci.org)
  • Buserelin induces apoptotic cell death and decreased diameter and epithelium thickness of seminiferous tubules in the adult rat testes . (bvsalud.org)
  • Buserelin and normal saline were injected subcutaneously for five days. (uwi.edu)
  • The first and second treated groups received 300 (low dose ) and 500 (high dose ) µg/kg buserelin , respectively, and the control group received normal saline . (bvsalud.org)
  • All patients received buserelin, 500 micrograms q 8 hours subcutaneously (s.c.) for the first 7 days and then elected to take 200 micrograms s.c. daily or 400 micrograms q 8 hours by the intranasal (i.n.) route. (elsevier.com)
  • Intranasal buserelin has also been used in 1 patient to prevent premenstrual exacerbation of coproporphyria. (sexualhealthmedicine.com)
  • The findings of this study suggest that short-term administration of high dose buserelin increases the serum estradiol level and apoptosis in the granulosa cells but has an inhibitory effect on follicular development. (uwi.edu)
  • Serum estradiol level was significantly lower in the cetrorelix than in the buserelin group (mean ± SD: 2600.58 ± 1189.11 vs. 3293.46 ± 1221.49 pg/ml, p = 0.006), but the endometrial thickness was similar. (elsevier.com)
  • Buserelin is approved for the treatment of hormone-responsive cancers including prostate cancer and premenopausal breast cancer, sex hormone-dependent uterine diseases including endometrial hyperplasia, endometriosis, and uterine fibroids, and in assisted reproduction for female infertility. (wikipedia.org)
  • Buserelin is also used to treat endometriosis . (patient.info)
  • Gonadorelin analogues such as buserelin have a role in the management of endometriosis, but the need for long-term therapy limits their value because of the risk of osteoporosis 'add-back' therapy (hormone replacement) can be used to prevent this. (sexualhealthmedicine.com)
  • Like other gonadorelin analogues buserelin has been used to reduce the volume of uterine fibroids. (sexualhealthmedicine.com)
  • The remaining seven dogs were given a second dose of buserelin , equal to the first administration . (bvsalud.org)
  • In ovulation induction, buserelin is used for pituitary suppression as an adjunct to gonadotropin administration. (wikipedia.org)
  • Gonadotrophin treatment is then added to buserelin therapy until an appropriate stage of follicular development, when both are withdrawn and chorionic gonadotrophin is given to induce ovulation. (sexualhealthmedicine.com)
  • Buserelin is given with gonadotrophic hormone therapy for induction of ovulation and as an aid to improving IVF procedures. (sexualhealthmedicine.com)
  • For prostate cancer, the dosage of buserelin by subcutaneous injection is 500 μg three times per day (once every 8 hours, 1,500 μg/day total) for one week and then 200 μg once daily thereafter. (wikipedia.org)
  • Buserelin is used for the treatment of hormone-dependent cancer of the prostate gland (prostate cancer). (dd-database.org)
  • Efficacy of buserelin in advanced prostate cancer and comparison with historical controls. (elsevier.com)
  • Sixty women were stimulated with the CC/hMG/cetrorelix protocol (cetrorelix group) and 60 received the buserelin long protocol (buserelin group). (elsevier.com)
  • 0.001) of gonadotropin used were significantly lower in the cetrorelix group than in the buserelin group. (elsevier.com)
  • Buserelin is a synthetic form of a hormone which occurs naturally in your body. (patient.info)
  • Read also the information about the active group of hypothalamic hormones, among which the active ingredient of Buserelin. (dd-database.org)
  • What side effects can the active ingredient of Buserelin in Pro fact per injectione have? (dd-database.org)
  • In summary, buserelin reliably lowers the serum T level by week 4 in 95% of men. (elsevier.com)
  • Total GI transit time, galactose absorption, zonulin levels in plasma, and antibody titers in serum were unaffected by buserelin treatment. (biomedcentral.com)
  • The aim of the present study was to investigate the effects of buserelin on the development of follicles, apoptosis index, and steroid hormones level. (uwi.edu)
  • Long-acting subcutaneous depot preparations that release buserelin over a 2- or 3-month period are also available. (sexualhealthmedicine.com)
  • Buserelin reduces the production of female sex hormones by acting on your pituitary gland. (patient.info)
  • By reducing the levels of these hormones, buserelin will help to relieve your symptoms. (patient.info)
  • Buserelin is among the Group of hypothalamic hormones and is a synthetically-produced hormone that is similar to a natural releasing hormone in the midbrain. (dd-database.org)
  • Buserelin with gonadotrophic hormones has been found to result in pregnancies in women previously unresponsive to clomifene citrate, although there may be a greater risk of multiple births. (sexualhealthmedicine.com)
  • A marked enteric neuronal loss with modest effects on GI function is found after buserelin treatment. (biomedcentral.com)
  • DI-fusion Combined treatment with buserelin and tamoxifen in. (ac.be)
  • Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. (ac.be)
  • The administration of buserelin was effective in inducing estrus in female dogs during the anestrous phase, with a maximum of two administrations. (bvsalud.org)
  • Buserelin appears to be safe in the event of an overdose. (wikipedia.org)
  • Buserelin stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). (newdrugapprovals.org)
  • I'm on day 27 of my cycle (8 days on buserelin) although I know not entirely abnormal to be late. (healthunlocked.com)
  • In addition, buserelin is used in veterinary medicine. (wikipedia.org)
  • Other reports of malignant neoplasms treated with buserelin include its use in metastatic breast cancer. (sexualhealthmedicine.com)